Literature DB >> 12824878

Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma.

Yusuke Oji1, Hidenori Inohara, Mitsuhiro Nakazawa, Yoko Nakano, Shiro Akahani, Shin-ichi Nakatsuka, Satoko Koga, Ai Ikeba, Sakie Abeno, Yuichiro Honjo, Yoshifumi Yamamoto, Soichi Iwai, Kaori Yoshida, Yoshihiro Oka, Hiroyasu Ogawa, Jun-ichi Yoshida, Katsuyuki Aozasa, Takeshi Kubo, Haruo Sugiyama.   

Abstract

The expression levels of the Wilms' tumor gene WT1 were examined in 56 cases of head and neck squamous cell carcinoma (HNSCC) using quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR). They included 4 cases of floor of mouth, 9 of gingiva, 25 of tongue, 10 of oropharynx, 3 of hypopharynx, and 5 larynx squamous cell carcinoma (SCC). All (100%) of 4 cases of floor of mouth, 5 (56%) of 9 gingiva, 17 (68%) of 25 tongue, 8 (80%) of 10 oropharynx, all (100%) of 3 hypopharynx, and all (100%) of 5 larynx SCC overexpressed the WT1 gene in the range of 3.07 x 10(-4)-8.60 x 10(-1) levels (the WT1 expression level in K562 leukemic cells was defined as 1.0). Thus, 42 (75%) out of 56 cases of HNSCC overexpressed the WT1 gene. The high expression level of the WT1 gene significantly correlated with poor histological tumor differentiation and high tumor stage of HNSCC. Immunohistochemical analysis confirmed the expression of WT1 protein in 6 cases (one floor of mouth, 2 tongue, 2 oropharynx, and one larynx SCC) with overexpression of the WT1 gene. The direct sequencing analysis of the WT1 genomic DNA showed no mutations in any of 10 exons of the WT1 gene in 5 different HNSCC. These findings suggest an important role of the wild-type WT1 gene in the tumorigenesis of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824878     DOI: 10.1111/j.1349-7006.2003.tb01477.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  13 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

2.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

3.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 4.  Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.

Authors:  Eric I Marks; Nelson S Yee
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

5.  Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma.

Authors:  A G Schache; G Hall; J A Woolgar; G Nikolaidis; A Triantafyllou; D Lowe; J M Risk; R J Shaw; T Liloglou
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

6.  Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck.

Authors:  Xingru Li; Sofia Ottosson; Sihan Wang; Emma Jernberg; Linda Boldrup; Xiaolian Gu; Karin Nylander; Aihong Li
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

7.  The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.

Authors:  Keiko Yamanouchi; Tsuyoshi Ohta; Zhiyang Liu; Yusuke Oji; Haruo Sugiyama; Viji Shridhar; Sohei Matsumura; Toshifumi Takahashi; Kazuhiro Takahashi; Hirohisa Kurachi
Journal:  Transl Oncol       Date:  2014-10-24       Impact factor: 4.243

8.  Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.

Authors:  Hyun-Jung Sohn; Ji Yoon Lee; Hyun-Joo Lee; Dae-Hee Sohn; Hyun-Il Cho; Hee-Je Kim; Tai-Gyu Kim
Journal:  Oncotarget       Date:  2017-07-04

9.  Wilms' tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling.

Authors:  Yun Han; Chao Song; Tingting Zhang; Qianqian Zhou; Xiaoqian Zhang; Jing Wang; Boqun Xu; Xuesen Zhang; Xiaoqiu Liu; Xiaoyan Ying
Journal:  Cell Cycle       Date:  2020-09-07       Impact factor: 4.534

10.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.